Published in Nature on June 26, 2002
Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol (2003) 6.21
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A (2002) 6.09
Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res (2003) 3.85
RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci U S A (2003) 3.48
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci U S A (2002) 3.21
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
Human immunodeficiency virus type 1 escape from RNA interference. J Virol (2003) 3.01
Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A (2003) 3.00
HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93
Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A (2003) 2.64
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci U S A (2002) 2.43
Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A (2003) 2.34
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Macrophages archive HIV-1 virions for dissemination in trans. EMBO J (2005) 2.27
Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol (2003) 2.26
A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2009) 2.25
Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett (2005) 2.22
HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol (2007) 2.20
Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep (2003) 2.16
HIV-1 nef suppression by virally encoded microRNA. Retrovirology (2004) 2.05
Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res (2004) 2.02
Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J Virol (2005) 1.98
Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood (2007) 1.93
Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest (2011) 1.92
Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A (2004) 1.91
Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett (2009) 1.86
RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci U S A (2003) 1.84
Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing. J Virol (2003) 1.81
RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol (2002) 1.80
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol (2005) 1.80
Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol (2003) 1.73
RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J Nanosci Nanotechnol (2005) 1.68
Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol (2004) 1.61
A computational study of off-target effects of RNA interference. Nucleic Acids Res (2005) 1.60
Latency: the hidden HIV-1 challenge. Retrovirology (2006) 1.59
Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. J RNAi Gene Silencing (2005) 1.57
Effects of length and location on the cellular response to double-stranded RNA. Microbiol Mol Biol Rev (2004) 1.57
Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood (2005) 1.54
Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J Virol (2004) 1.52
Murine gammaherpesvirus 68 open reading frame 31 is required for viral replication. J Virol (2004) 1.40
Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA. Nucleic Acids Res (2003) 1.35
HIV infection of non-dividing cells: a divisive problem. Retrovirology (2006) 1.33
La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA. J Virol (2005) 1.31
Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand. J Virol (2005) 1.30
Medicine: silencing viruses with RNA. Nature (2002) 1.27
A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res (2007) 1.27
Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol (2004) 1.26
Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol (2003) 1.25
An enhanced U6 promoter for synthesis of short hairpin RNA. Nucleic Acids Res (2003) 1.24
Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs. RNA (2013) 1.24
Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration. J Virol (2006) 1.21
Actively replicating West Nile virus is resistant to cytoplasmic delivery of siRNA. Virol J (2005) 1.21
Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano (2010) 1.21
Derivation of normal macrophages from human embryonic stem (hES) cells for applications in HIV gene therapy. Retrovirology (2006) 1.21
The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology (2006) 1.20
Short interfering RNA-mediated interference of gene expression and viral DNA accumulation in cultured plant cells. Proc Natl Acad Sci U S A (2003) 1.20
Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther (2012) 1.19
Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther (2009) 1.18
RNA interference targeting VP1 inhibits foot-and-mouth disease virus replication in BHK-21 cells and suckling mice. J Virol (2004) 1.16
RNA interference: the molecular immune system. J Mol Histol (2004) 1.16
RNA interference of four genes in adult Bactrocera dorsalis by feeding their dsRNAs. PLoS One (2011) 1.15
Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci U S A (2006) 1.15
Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol (2006) 1.12
Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells. Nat Protoc (2013) 1.11
Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced by human immunodeficiency virus type 1 viral protein R. J Virol (2004) 1.11
Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus. Nucleic Acids Res (2004) 1.10
Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape. J Virol (2005) 1.10
CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology (2005) 1.10
Inhibition of gammaherpesvirus replication by RNA interference. J Virol (2003) 1.08
HIV-1 gp120-mediated increases in IL-8 production in astrocytes are mediated through the NF-κB pathway and can be silenced by gp120-specific siRNA. J Neuroinflammation (2010) 1.08
Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach. J Virol (2004) 1.08
HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host Microbe (2008) 1.07
Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol (2006) 1.07
RNA interference directed against Poly(ADP-Ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells. J Virol (2004) 1.07
Intracellular approach for blocking JC virus gene expression by using RNA interference during viral infection. J Virol (2004) 1.06
Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res (2007) 1.06
A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J RNAi Gene Silencing (2005) 1.06
A simple and cost-effective method for producing small interfering RNAs with high efficacy. Nucleic Acids Res (2003) 1.06
Molecular strategies to inhibit HIV-1 replication. Retrovirology (2005) 1.05
HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther (2005) 1.05
Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5. Genet Vaccines Ther (2009) 1.05
Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. Retrovirology (2004) 1.05
Uncoupling of RNAi from active translation in mammalian cells. RNA (2004) 1.04
Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells. Methods (2011) 1.03
Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action. J Virol (2003) 1.02
Novel insights into RNAi off-target effects using C. elegans paralogs. BMC Genomics (2007) 1.00
Suppression of vascular endothelial growth factor expression at the transcriptional and post-transcriptional levels. Nucleic Acids Res (2005) 1.00
Elimination pathways of systemically delivered siRNA. Mol Ther (2010) 0.99
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog (2011) 0.97
RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2005) 0.97
Enrichment of intersubtype HIV-1 recombinants in a dual infection system using HIV-1 strain-specific siRNAs. Retrovirology (2011) 0.97
Use of modified U1 snRNAs to inhibit HIV-1 replication. Nucleic Acids Res (2006) 0.96
RNA interference: antiviral weapon and beyond. World J Gastroenterol (2003) 0.95
Trans-inhibition of HIV-1 by a long hairpin RNA expressed within the viral genome. Retrovirology (2007) 0.95
Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther (2013) 0.95
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A (2014) 2.95
HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature (2003) 2.90
Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol (2008) 2.83
Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog (2008) 2.72
A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection. Cell Host Microbe (2009) 2.34
Macrophages archive HIV-1 virions for dissemination in trans. EMBO J (2005) 2.27
The inner-nuclear-envelope protein emerin regulates HIV-1 infectivity. Nature (2006) 2.02
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol (2005) 1.80
Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog (2007) 1.61
Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J Virol (2004) 1.52
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther (2011) 1.41
Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog (2011) 1.32
Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe (2008) 1.31
Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci U S A (2002) 1.27
Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol (2004) 1.26
Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med (2002) 1.23
Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog (2011) 1.21
Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs. J Leukoc Biol (2006) 1.19
In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. MBio (2013) 1.18
Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS (2013) 1.17
Modest but reproducible inhibition of human immunodeficiency virus type 1 infection in macrophages following LEDGFp75 silencing. J Virol (2006) 1.14
HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions. J Leukoc Biol (2003) 1.13
Importin 7 may be dispensable for human immunodeficiency virus type 1 and simian immunodeficiency virus infection of primary macrophages. J Virol (2005) 1.06
Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. Retrovirology (2004) 1.05
The search for a cure for persistent HIV reservoirs. AIDS Rev (2011) 0.98
The majority of freshly sorted simian immunodeficiency virus (SIV)-specific CD8(+) T cells cannot suppress viral replication in SIV-infected macrophages. J Virol (2012) 0.97
Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem (2009) 0.95
HIV type 1 infection up-regulates TLR2 and TLR4 expression and function in vivo and in vitro. AIDS Res Hum Retroviruses (2012) 0.89
HIV-1 replication increases HIV-specific CD4+ T cell frequencies but limits proliferative capacity in chronically infected children. J Immunol (2003) 0.89
A highly conserved residue in the C-terminal helix of HIV-1 matrix is required for envelope incorporation into virus particles. J Virol (2011) 0.89
Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication. ChemMedChem (2012) 0.87
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. J Acquir Immune Defic Syndr (2013) 0.86
Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus. J Virol (2010) 0.81
A novel motif in HIV-1 Nef that regulates MIP-1beta chemokine release in macrophages. J Virol (2010) 0.80
Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir. AIDS Res Hum Retroviruses (2015) 0.77
TRIMming HIV-1's mainsail. Nat Immunol (2004) 0.76
Tat's seductive side. Nat Med (2003) 0.75
Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure. AIDS Res Ther (2012) 0.75
A plea for justice for jailed medical workers. Science (2006) 0.75
Unsung hero Robert C. Gallo. Science (2009) 0.75
Zika Virus: Obstetric and Pediatric Anesthesia Considerations. Anesth Analg (2017) 0.75